Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE)
Source: View publication →
In patients with high-risk transient ischemic attack or minor ischemic stroke, the administration of dual antiplatelet therapy with clopidogrel and aspirin for 21 days significantly reduced the risk of subsequent stroke within 90 days without increasing the risk of hemorrhage compared to aspirin monotherapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CHANCE trial provided critical evidence supporting the use of short-term dual antiplatelet therapy immediately following high-risk TIA or minor ischemic stroke, shifting clinical practice toward more aggressive early intervention to address the period of highest recurrence risk, while maintaining a favorable safety profile regarding bleeding.
Historical Context
Prior trials, such as MATCH and CHARISMA, evaluated long-term dual antiplatelet therapy in stroke patients and found no significant benefit but increased bleeding risks. CHANCE was designed to test whether initiating therapy in the acute, hyper-early phase (within 24 hours) with a limited 21-day course of dual agents could circumvent these risks and capitalize on the high early recurrence rate of ischemic events.
Guided Discussion
High-yield insights from every perspective
What is the biological rationale for using dual antiplatelet therapy (DAPT) with clopidogrel and aspirin rather than aspirin alone in the immediate aftermath of a minor ischemic stroke?
Key Response
Aspirin inhibits thromboxane A2 production via the COX-1 pathway, while clopidogrel blocks the P2Y12 adenosine diphosphate (ADP) receptor. Because these drugs target distinct and complementary pathways of platelet activation and aggregation, their combination provides a synergistic effect that is more effective at preventing thrombus propagation during the 'hyperacute' period when the risk of recurrence is highest.
Based on the CHANCE trial inclusion criteria, which specific patient population with Transient Ischemic Attack (TIA) should be considered for 21 days of DAPT, and what scoring system is used to identify them?
Key Response
The CHANCE trial specifically targeted 'high-risk' TIA patients, defined as those with an ABCD2 score of 4 or higher. This score accounts for Age, Blood pressure, Clinical features, Duration of symptoms, and Diabetes. Identifying this high-risk cohort is essential because the benefit of DAPT in preventing early recurrence outweighs the potential bleeding risks specifically in this group, whereas low-risk TIA patients may not derive the same net benefit.
Contrast the DAPT duration and loading dose strategies used in the CHANCE trial versus the later POINT trial. How do these differences influence the risk-benefit profile regarding major hemorrhage?
Key Response
CHANCE used a 300mg clopidogrel load and 21 days of DAPT, while POINT used a 600mg load and 90 days of DAPT. While both showed a reduction in ischemic events, POINT found a significantly higher risk of major hemorrhage that emerged primarily after the first 3 weeks of therapy. This suggests that the maximal benefit for stroke prevention is front-loaded in the first 21 days, after which the risk of bleeding may outweigh the preventative benefit.
The CHANCE trial emphasized initiating treatment within 24 hours of symptom onset. How has this specific time window changed the clinical approach to 'minor' symptoms in the emergency department, and what are the implications for patients who present at 48 hours?
Key Response
The trial solidified the concept that minor stroke and TIA are medical emergencies requiring 'ultra-early' intervention. The efficacy of the CHANCE protocol is tied to starting within 24 hours; for patients presenting later, the evidence for DAPT benefit is less robust because the highest risk of recurrence has already passed, highlighting the need for rapid triage and treatment systems equivalent to those used for major strokes.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Given that the CHANCE trial was conducted entirely in China, how do population-specific frequencies of CYP2C19 loss-of-function alleles potentially limit the external validity of these findings to a broader global population?
Key Response
CYP2C19 loss-of-function (LOF) alleles, which reduce the conversion of clopidogrel to its active metabolite, are present in approximately 50% of East Asian populations compared to about 25-30% of White populations. If clopidogrel is less effective in LOF carriers, the 'true' efficacy of the DAPT regimen might actually be higher in Western populations, or conversely, different genetic predispositions toward bleeding could alter the safety profile, necessitating localized validation.
As a reviewer, what are the potential threats to internal validity regarding the 'minor stroke' definition used in CHANCE (NIHSS ≤ 3), particularly concerning the lack of mandatory baseline MRI imaging for all participants?
Key Response
An NIHSS of 3 can represent very different clinical states (e.g., isolated aphasia vs. multiple minor motor deficits). Without mandatory MRI, it is impossible to distinguish between a TIA and a small tissue-positive infarct in all cases. This heterogeneity means the treatment effect might be driven by a specific subgroup (e.g., large-artery atherosclerosis) that remained hidden due to the lack of standardized neuroimaging, complicating the precision of the trial's conclusions.
How do the results of the CHANCE trial align with current AHA/ASA guidelines regarding the duration of DAPT for secondary stroke prevention, and what is the current Class and Level of recommendation for this intervention?
Key Response
Current AHA/ASA guidelines (e.g., 2021/2022 updates) recommend that patients with minor ischemic stroke (NIHSS ≤ 3) or high-risk TIA (ABCD2 ≥ 4) should receive DAPT started within 24 hours and continued for 21 to 90 days, followed by antiplatelet monotherapy. This is a Class I, Level of Evidence A recommendation, directly supported by the CHANCE and POINT trials which demonstrated that early, short-term DAPT significantly reduces 90-day stroke recurrence.
Clinical Landscape
Noteworthy Related Trials
MATCH Trial
Tested
Clopidogrel plus aspirin
Population
High-risk patients with recent ischemic stroke or TIA
Comparator
Clopidogrel alone
Endpoint
Composite of ischemic stroke, MI, vascular death, or rehospitalization
SPS3 Trial
Tested
Clopidogrel plus aspirin
Population
Patients with symptomatic lacunar stroke
Comparator
Aspirin alone
Endpoint
Recurrent stroke
POINT Trial
Tested
Clopidogrel plus aspirin
Population
Patients with minor ischemic stroke or high-risk TIA
Comparator
Aspirin alone
Endpoint
Composite of major ischemic events (ischemic stroke, MI, or death)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis